Vertaling van "cancer amongst women aged 40-49 " (Frans → Nederlands) :

Table 20 : Invasive breast cancer and in situ breast cancer amongst women aged 40-49, observed and estimated incidence rate / 100.000 women per year in Flanders (Belgium) (1999-2006)
Table 20: Invasive breast cancer and in situ breast cancer amongst women aged 40-49, observed and estimated incidence rate / 100.000 women per year in Flanders (Belgium) (1999-2006)

Table 22 : Evolution of interventions in time amongst women 40 - 49 (Belgium) per 100 000 women (2002-2008).
Table 22: Evolution of interventions in time amongst women 40 - 49 (Belgium) per 100 000 women (2002-2008).

Table 10: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)
Table 8: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)

Table 11: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Crude RR and and RR adjusted following Cuzick (1997) 22 Study ID study
Table 9: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Crude RR and and RR adjusted following Cuzick (1997) 21 Study ID study

Breast cancer (age group 40 - 49) : observed and estimated specific mortality rate / 100 000 women per year in Flanders (Belgium) (1999-2006)
Breast cancer (age group 40 - 49): observed and estimated specific mortality rate / 100 000 women per year in Flanders (Belgium) (1999-2006)

13. Ringash J. Preventive health care, 2001 update: screening mammography among women aged 40-49 years at average risk of breast cancer.
12. Ringash J. Preventive health care, 2001 update: screening mammography among women aged 40-49 years at average risk of breast cancer.

A la demande de l’INAMI, le Centre fédéral d’expertise des soins de santé (KCE) a fait le point sur l’opportunité de dépister le cancer du sein chez les femmes âgées de 40 à 49 ans ne présentant pas de symptômes ou de risque familial élevé particulier.
Op vraag van het RIZIV ging het Federaal Kenniscentrum voor de Gezondheidszorg (KCE) na of het zinvol is om gezonde vrouwen tussen 40 en 49 jaar, zonder symptomen of zonder verhoogd risico in de familie, te screenen op borstkanker.

A la demande de l’INAMI, le KCE (Centre fédéral d’expertise des soins de santé) a fait le point sur l’opportunité de dépister systématiquement le cancer du sein chez les femmes âgées de 40 à 49 ans ne présentant pas de symptômes ou de risque familial élevé particulier.
Op verzoek van het RIZIV onderzocht het KCE (het federaal Kenniscentrum voor de Gezondheidszorg) of het opportuun is om systematisch borstkanker op te sporen bij vrouwen tussen 40 en 49 jaar die geen symptomen of familierisico vertonen.